Business highlights in Q4 2022
- On October 4th the Company announced the outcome of the incentive program ‘LTI2022’ approved by the AGM on May 24th 2022.
- On November 4th the Company provided an update on its clinical programs.
- On December 20th the Company started a Phase 1 pharmacokinetics study for new IP2015 formulations.
- On December 23rd the Company announced that it had decided not to exercise the option for an undisclosed pain asset.
Business highlights after this reporting period
- Nothing to report.
Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK).
|Fourth Quarter (2022-10-01 – 2022-12-31)|
|Net revenue were TDKK 0 (0)|
|Operating loss, EBIT was TDKK -6,477 (-7,280)|
|Earnings per share was DKK –0.06 (-0.11)|
|Cash: TDKK 39,112 (34,346)|
|Solidity: 72% (92%)|
|Full Year (2022-01-01 – 2022-12-31)|
|Net revenues were TDKK 0 (0)|
|Operating loss, EBIT was TDKK -41,740 (-23,072)|
|Earnings per share was DKK –0.73 (-0.60)|
As disclosed in the Q1:2022 report Initiator Pharma publishes its interim reports in English only.
Link to the full report